Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Journal of Neuro-Oncology
Erschienen in:

02.05.2023 | Research

Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model

verfasst von: Laiz Laura de Godoy, Sanjeev Chawla, Steven Brem, Sumei Wang, Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai, Laurie A. Loevner, Linda M. Liau, Suyash Mohan

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) is a promising treatment modality for glioblastomas. The purpose of this study was to investigate the potential utility of multiparametric MRI-based prediction model in evaluating treatment response in glioblastoma patients treated with DCVax-L.

Methods

Seventeen glioblastoma patients treated with standard-of-care therapy + DCVax-L were included. When tumor progression (TP) was suspected and repeat surgery was being contemplated, we sought to ascertain the number of cases correctly classified as TP + mixed response or pseudoprogression (PsP) from multiparametric MRI-based prediction model using histopathology/mRANO criteria as ground truth. Multiparametric MRI model consisted of predictive probabilities (PP) of tumor progression computed from diffusion and perfusion MRI-derived parameters. A comparison of overall survival (OS) was performed between patients treated with standard-of-care therapy + DCVax-L and standard-of-care therapy alone (external controls). Additionally, Kaplan–Meier analyses were performed to compare OS between two groups of patients using PsP, Ki-67, and MGMT promoter methylation status as stratification variables.

Results

Multiparametric MRI model correctly predicted TP + mixed response in 72.7% of cases (8/11) and PsP in 83.3% (5/6) with an overall concordance rate of 76.5% with final diagnosis as determined by histopathology/mRANO criteria. There was a significant concordant correlation coefficient between PP values and histopathology/mRANO criteria (r = 0.54; p = 0.026). DCVax-L-treated patients had significantly prolonged OS than those treated with standard-of-care therapy (22.38 ± 12.8 vs. 13.8 ± 9.5 months, p = 0.040). Additionally, glioblastomas with PsP, MGMT promoter methylation status, and Ki-67 values below median had longer OS than their counterparts.

Conclusion

Multiparametric MRI-based prediction model can assess treatment response to DCVax-L in patients with glioblastoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
2.
Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM (2020) Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep 10(1):11622
3.
Montoya ML, Kasahara N, Okada H (2020) Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neurooncol Pract 7:465–476PubMedPubMedCentral
4.
5.
Boussiotis VA, Charest A (2018) Immunotherapies for malignant glioma. Oncogene 37:1121–1141PubMedCrossRef
6.
Prins RM, Craft N, Bruhn KW et al (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176:157–164PubMedCrossRef
7.
Prins RM, Soto H, Konkankit V et al (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615PubMedCrossRef
8.
9.
Liau LM, Ashkan K, Tran DD et al (2018) First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16:142PubMedPubMedCentralCrossRef
10.
Liau LM, Ashkan K, Brem S et al (2022) Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma. JAMA Oncol 9:112–121PubMedCentralCrossRef
11.
Chawla S, Shehu V, Gupta PK et al (2021) Physiological imaging methods for evaluating response to immunotherapies in glioblastomas. Int J Mol Sci 22:3867PubMedPubMedCentralCrossRef
12.
da Cruz LCH, da Cruz LCH, Rodriguez I et al (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol 32:1978–1985CrossRef
13.
Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534–e542PubMedPubMedCentralCrossRef
14.
Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14:307–320PubMedPubMedCentralCrossRef
15.
Qin L, Li X, Stroiney A et al (2017) Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. Neuroradiology 59:135–145PubMedPubMedCentralCrossRef
16.
Song J, Kadaba P, Kravitz A et al (2020) Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro Oncol 22:1658–1666PubMedPubMedCentralCrossRef
17.
Wang S, O’Rourke DM, Chawla S et al (2019) Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. Br J Cancer 120:54–56PubMedCrossRef
18.
Vrabec M, Van Cauter S, Himmelreich U et al (2011) MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology 53:721–731PubMedCrossRef
19.
Stenberg L, Englund E, Wirestam R et al (2006) Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme. Acta radiol 47:852–861PubMedCrossRef
20.
Wang S, Martinez-Lage M, Sakai Y et al (2016) Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol 37:28–36PubMedPubMedCentralCrossRef
21.
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251PubMedPubMedCentralCrossRef
22.
Verma G, Chawla S, Mohan S et al (2019) Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. NMR Biomed 32:e4042PubMedCrossRef
23.
Bagley SJ, Schwab RD, Nelson E et al (2019) Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma. J Neurooncol 141:421–429PubMedCrossRef
24.
Akbari H, Rathore S, Bakas S et al (2020) Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. Cancer 126:2625–2636PubMedCrossRef
25.
Mohan S, Wang S, Coban G et al (2019) Detection of occult neoplastic infiltration in the corpus callosum and prediction of overall survival in patients with glioblastoma using diffusion tensor imaging. Eur J Radiol 112:106–111PubMedCrossRef
26.
Rahman R, Ventz S, McDunn J et al (2021) Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol 22:e456–e465PubMedPubMedCentralCrossRef
27.
Wang S, Kim S, Chawla S et al (2009) Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage 44:653–660PubMedCrossRef
28.
Chawla S, Wang S, Mohan S et al (2019) Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI. J Magn Reson Imaging 49:184–194PubMedCrossRef
29.
Nasrallah MP, Binder ZA, Oldridge DA et al (2019) Molecular neuropathology in practice: clinical profiling and integrative analysis of molecular alterations in glioblastoma. Acad Pathol 6:2374289519848353PubMedPubMedCentralCrossRef
30.
Kasten BB, Udayakumar N, Leavenworth JW et al (2019) Current and future imaging methods for evaluating response to immunotherapy in neuro-oncology. Theranostics 9:5085–5104PubMedPubMedCentralCrossRef
31.
Liau LM, Prins RM, Kiertscher SM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515–5525PubMedCrossRef
32.
Ellingson BM, Sampson J, Achrol AS et al (2021) Modified RANO, immunotherapy RANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma. Clin Cancer Res 27:3916–3925PubMedPubMedCentralCrossRef
33.
34.
35.
Rowe LS, Butman JA, Mackey M et al (2018) Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM. J Neurooncol 139:145–152PubMedPubMedCentralCrossRef
36.
Zikou A, Sioka C, Alexiou GA et al (2018) Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Med Mol Imaging 2018:6828396CrossRef
37.
Mohan S, Wang S, Chawla S et al (2021) Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma. Surg Neurol Int 12:337PubMedPubMedCentralCrossRef
38.
Gerstner ER, McNamara MB, Norden AD et al (2009) Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 94:97–101PubMedCrossRef
39.
Gunjur A, Lau E, Taouk Y, Ryan G (2011) Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. J Med Imaging Radiat Oncol 55:603–610PubMedCrossRef
40.
Kang H-C, Kim C-Y, Han JH et al (2011) Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. J Neurooncol 102:157–162PubMedCrossRef
41.
Sanghera P, Perry J, Sahgal A et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37:36–42PubMedCrossRef
42.
Van Mieghem E, Wozniak A, Geussens Y et al (2013) Defining pseudoprogression in glioblastoma multiforme. Eur J Neurol 20:1335–1341PubMedCrossRef
43.
Li H, Li J, Cheng G et al (2016) IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Clin Neurol Neurosurg 151:31–36PubMedCrossRef
44.
Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39–51PubMedCrossRef
45.
Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR et al (2022) External control arms in oncology: current use and future directions. Ann Oncol 33:376–383PubMedCrossRef
Metadaten
Titel
Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model
verfasst von
Laiz Laura de Godoy
Sanjeev Chawla
Steven Brem
Sumei Wang
Donald M. O’Rourke
MacLean P. Nasrallah
Arati Desai
Laurie A. Loevner
Linda M. Liau
Suyash Mohan
Publikationsdatum
02.05.2023
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-023-04324-4

Weitere Artikel der Ausgabe 1/2023

Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma

  • Open Access
  • Research

Volumetric hippocampal changes in glioblastoma: a biomarker for neuroplasticity?

  • Open Access
  • Case Study

Anatomical and surgical characteristics correlate with pachymeningeal failure in patients with brain metastases after neurosurgical resection and adjuvant stereotactic radiosurgery

  • Case Study

Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol

  • Research

A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma

  • Research

Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET

  • Open Access
  • Research

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

CGRP-Antikörper auch bei älteren Migränekranken sicher

Beginnen ältere Migränekranke eine Prophylaxe mit CGRP-Antikörpern, kommt es anschließend nicht häufiger zu kardiovaskulären Problemen als unter einer Prophylaxe mit Botulinumtoxin. Darauf deutet eine US-Analyse von Medicare-Versicherten.

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Migräne verstehen und psychotherapeutisch behandeln

Das Wissen über die Mechanismen, die im Gehirn bei einer Migräneattacke ablaufen, und mögliche Auslöser wird immer breiter. Der psychologische Psychotherapeut Dr. Dipl.-Psych. Timo Klan fasst den aktuellen Erkenntnisstand zusammen. Und er gibt Tipps für eine differenzierte, individuelle Diagnostik auch von Begleiterkrankungen und beschreibt erfolgreiche psychotherapeutische Interventionen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise